Arista Wealth Management LLC Has $410,000 Stock Holdings in AstraZeneca PLC $AZN

Arista Wealth Management LLC lowered its stake in shares of AstraZeneca PLC (NASDAQ:AZN) by 42.8% during the 3rd quarter, Holdings Channel.com reports. The firm owned 5,342 shares of the company’s stock after selling 4,000 shares during the quarter. Arista Wealth Management LLC’s holdings in AstraZeneca were worth $410,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Chapin Davis Inc. boosted its holdings in AstraZeneca by 3.3% in the third quarter. Chapin Davis Inc. now owns 3,795 shares of the company’s stock worth $291,000 after acquiring an additional 120 shares in the last quarter. CoreCap Advisors LLC raised its position in shares of AstraZeneca by 30.6% during the third quarter. CoreCap Advisors LLC now owns 534 shares of the company’s stock worth $41,000 after purchasing an additional 125 shares during the period. Highline Wealth Partners LLC lifted its holdings in shares of AstraZeneca by 32.0% in the 3rd quarter. Highline Wealth Partners LLC now owns 532 shares of the company’s stock worth $41,000 after purchasing an additional 129 shares in the last quarter. Traub Capital Management LLC grew its position in AstraZeneca by 3.3% in the 3rd quarter. Traub Capital Management LLC now owns 4,115 shares of the company’s stock valued at $316,000 after purchasing an additional 130 shares during the period. Finally, Aaron Wealth Advisors LLC increased its stake in AstraZeneca by 0.6% during the 3rd quarter. Aaron Wealth Advisors LLC now owns 21,215 shares of the company’s stock valued at $1,628,000 after purchasing an additional 136 shares in the last quarter. Institutional investors own 20.35% of the company’s stock.

AstraZeneca Stock Performance

AstraZeneca stock opened at $188.40 on Tuesday. AstraZeneca PLC has a 1-year low of $122.48 and a 1-year high of $193.97. The company has a current ratio of 0.88, a quick ratio of 0.69 and a debt-to-equity ratio of 0.54. The firm has a market capitalization of $292.19 billion, a PE ratio of 62.59, a price-to-earnings-growth ratio of 1.59 and a beta of 0.34. The firm’s 50 day simple moving average is $103.79 and its 200 day simple moving average is $89.45.

Analysts Set New Price Targets

A number of research firms have weighed in on AZN. Jefferies Financial Group assumed coverage on shares of AstraZeneca in a research note on Monday, October 27th. They issued a “buy” rating on the stock. Wall Street Zen downgraded AstraZeneca from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 17th. Citigroup initiated coverage on AstraZeneca in a report on Tuesday, January 27th. They set a “buy” rating for the company. Weiss Ratings restated a “buy (b)” rating on shares of AstraZeneca in a report on Wednesday, January 21st. Finally, HSBC reaffirmed a “buy” rating and set a $108.00 target price on shares of AstraZeneca in a research report on Wednesday, December 10th. Ten investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, AstraZeneca currently has an average rating of “Moderate Buy” and an average target price of $95.75.

AstraZeneca Profile

AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca’s operations span research and development, large-scale manufacturing, and commercial distribution, with a presence in developed and emerging markets worldwide.

The company focuses on several core therapy areas including oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology, and rare diseases.